No annual revenue total was found in ALZAMEND NEURO, INC.'s SEC filings.
Alzamend Neuro, Inc. (ALZN) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-9.10M
Operating cash flow (TTM)
$-6.84M
Free cash flow
—
EPS (TTM)
$-2.31
Dividend per share
None
Shares outstanding
4.79M
+65.4% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALZN (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- DE
- Headquarters
- Atlanta, GA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1677077
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Apr 30, 2026 |
FY 2025 Apr 30, 2025 |
FY 2024 Apr 30, 2024 |
FY 2023 Apr 30, 2023 |
FY 2022 Apr 30, 2022 |
|---|---|---|---|---|---|
| Operating income | -$8.8M | -$4.5M | -$9.9M | -$14.9M | -$12.3M |
| Net income | -$8.8M | -$4.5M | -$9.9M | -$14.9M | -$12.4M |
| Diluted EPS | -$2.63 | -$11.32 | -$132.33 | -$22.89 | — |
| Operating cash flow | -$8.1M | -$6.6M | -$8.3M | -$8.9M | -$6.6M |
| Total assets | $2.1M | $4.6M | $631,588 | $5.9M | $14.5M |
| Total liabilities | $1.3M | $634,761 | $3.2M | $2.9M | $1.2M |
| Stockholders' equity | $733,211 | $4.0M | -$2.6M | $3.0M | $13.4M |
| Cash and investments | $710,689 | $3.9M | $376,048 | $5.1M | $14.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 29, 2026 | Sep 29, 2026 |
| 10-Q | Quarterly report | Sep 10, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Material agreement, Listing notice, Unregistered share sale, Bylaw or fiscal year change
|
Aug 3, 2026 | Aug 3, 2026 |
| 10-K | Annual report | Jul 22, 2026 | Apr 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 21, 2026 | Jul 21, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Apr 17, 2026 | Apr 17, 2026 |
All 397 Alzamend Neuro, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.